SCHEMBL926699

SCHEMBL926699

Nc1ccc2oc(C3=COC(Cc4ccccc4)O3)cc(=O)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.48
SRC P12931 1/20 0.48
PLA2G2A P14555 2/20 0.40
PLA2G4A P47712 2/20 0.40
BCHE P06276 1/20 0.39
ALOX5 P09917 1/20 0.39
ACHE P22303 1/20 0.39
LCK P06239 1/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 3/20 0.38
TNKS O95271 3/20 0.38
TP53 P04637 2/20 0.38
CYP3A4 P08684 2/20 0.38
HPGD P15428 2/20 0.38
ADORA3 P0DMS8 2/20 0.38
GABRP O00591 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL925724 0.80 MAPT (0.41) BCHEALOX5ACHENPC1RAB9A
Hydrochloric Acid SCHEMBL926012 0.79 CSNK2A2 (0.37) PLA2G2APLA2G4ABCHEACHENPC1
Hydrochloric Acid SCHEMBL925808 0.76 NPC1 (0.36) ACHENPC1RAB9ASMN1; SMN2MAPK1
6-Aminoflavone SCHEMBL31550004 0.72 EGFR (0.82) EGFRSRCPLA2G2APLA2G4ALCK
6-Aminoflavone SCHEMBL926716 0.72 EGFR (0.82) EGFRSRCPLA2G2APLA2G4ALCK
SCHEMBL17786600 0.70 EGFR (0.82) EGFRSRCPLA2G2APLA2G4ALCK
SCHEMBL7666098 0.67 MAPT (0.58) NPC1RAB9ASMN1; SMN2MAPK1KMT2A
SCHEMBL7655744 0.67 NMUR2 (0.44) BCHEACHEMAPK1KMT2AMAPT
SCHEMBL7656081 0.67 MAPT (0.48) SMN1; SMN2MAPK1KMT2AMAPTTNKS
SCHEMBL17786454 0.66 NPC1 (0.71) EGFRSRCPLA2G2APLA2G4ALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372866-B2 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain ROTTAPHARM S.P.A. (IT) 2013-02-12 US disclosed
EP-2268628-B1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM SPA (IT) 2012-05-16 EP disclosed
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2011-01-06 US disclosed
EP-2268628-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN Rottapharm S.p.A. (IT) 2011-01-05 EP disclosed
WO-2009109230-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN NAT1, AADAC, OPRL1 EGFR 1202/4885SRC 896/4885PLA2G2A 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.